Tags

Type your tag names separated by a space and hit enter

Engineering immunomodulatory biomaterials for type 1 diabetes.
Nat Rev Mater. 2019 Jun; 4(6):429-450.NR

Abstract

A cure for type 1 diabetes (T1D) would help millions of people worldwide, but remains elusive thus far. Tolerogenic vaccines and beta cell replacement therapy are complementary therapies that seek to address aberrant T1D autoimmune attack and subsequent beta cell loss. However, both approaches require some form of systematic immunosuppression, imparting risks to the patient. Biomaterials-based tools enable localized and targeted immunomodulation, and biomaterial properties can be designed and combined with immunomodulatory agents to locally instruct specific immune responses. In this Review, we discuss immunomodulatory biomaterial platforms for the development of T1D tolerogenic vaccines and beta cell replacement devices. We investigate nano- and microparticles for the delivery of tolerogenic agents and autoantigens, and as artificial antigen presenting cells, and highlight how bulk biomaterials can be used to provide immune tolerance. We examine biomaterials for drug delivery and as immunoisolation devices for cell therapy and islet transplantation, and explore synergies with other fields for the development of new T1D treatment strategies.

Authors+Show Affiliations

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA. Interdisciplinary Graduate Program in Biomedical Sciences, University of Florida, Gainesville, FL, USA. University of Florida Diabetes Institute, Gainesville, FL, USA.Interdisciplinary Graduate Program in Biomedical Sciences, University of Florida, Gainesville, FL, USA.J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA.J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, USA. Interdisciplinary Graduate Program in Biomedical Sciences, University of Florida, Gainesville, FL, USA. University of Florida Diabetes Institute, Gainesville, FL, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32617176

Citation

Stabler, C L., et al. "Engineering Immunomodulatory Biomaterials for Type 1 Diabetes." Nature Reviews. Materials, vol. 4, no. 6, 2019, pp. 429-450.
Stabler CL, Li Y, Stewart JM, et al. Engineering immunomodulatory biomaterials for type 1 diabetes. Nat Rev Mater. 2019;4(6):429-450.
Stabler, C. L., Li, Y., Stewart, J. M., & Keselowsky, B. G. (2019). Engineering immunomodulatory biomaterials for type 1 diabetes. Nature Reviews. Materials, 4(6), 429-450. https://doi.org/10.1038/s41578-019-0112-5
Stabler CL, et al. Engineering Immunomodulatory Biomaterials for Type 1 Diabetes. Nat Rev Mater. 2019;4(6):429-450. PubMed PMID: 32617176.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Engineering immunomodulatory biomaterials for type 1 diabetes. AU - Stabler,C L, AU - Li,Y, AU - Stewart,J M, AU - Keselowsky,B G, Y1 - 2019/05/17/ PY - 2020/7/4/entrez PY - 2020/7/4/pubmed PY - 2020/7/4/medline SP - 429 EP - 450 JF - Nature reviews. Materials JO - Nat Rev Mater VL - 4 IS - 6 N2 - A cure for type 1 diabetes (T1D) would help millions of people worldwide, but remains elusive thus far. Tolerogenic vaccines and beta cell replacement therapy are complementary therapies that seek to address aberrant T1D autoimmune attack and subsequent beta cell loss. However, both approaches require some form of systematic immunosuppression, imparting risks to the patient. Biomaterials-based tools enable localized and targeted immunomodulation, and biomaterial properties can be designed and combined with immunomodulatory agents to locally instruct specific immune responses. In this Review, we discuss immunomodulatory biomaterial platforms for the development of T1D tolerogenic vaccines and beta cell replacement devices. We investigate nano- and microparticles for the delivery of tolerogenic agents and autoantigens, and as artificial antigen presenting cells, and highlight how bulk biomaterials can be used to provide immune tolerance. We examine biomaterials for drug delivery and as immunoisolation devices for cell therapy and islet transplantation, and explore synergies with other fields for the development of new T1D treatment strategies. SN - 2058-8437 UR - https://www.unboundmedicine.com/medline/citation/32617176/Engineering_immunomodulatory_biomaterials_for_type_1_diabetes L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/32617176/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.